The Chief Financial Officer of Renalytix AI (Other OTC: RTNXF) is Selling Shares

By Carrie Williams

Yesterday, the Chief Financial Officer of Renalytix AI (RTNXFResearch Report), O James Sterling, sold shares of RTNXF for $379.7K.

Following O James Sterling’s last RTNXF Sell transaction on July 23, 2021, the stock climbed by 1.4%.

See today’s analyst top recommended stocks >>

Based on Renalytix AI’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $619K and GAAP net loss of -$8,776,000. In comparison, last year the company earned revenue of $0 and had a GAAP net loss of $731K. The company has a one-year high of $17.15 and a one-year low of $5.35. Currently, Renalytix AI has an average volume of .

Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Renalytix AI PLC is a developer of artificial intelligence-enabled clinical decision support solutions for kidney disease and costly chronic medical conditions globally. The company’s solutions are being designed to make significant improvements in kidney disease risk assessment, clinical care, patient stratification for drug clinical trials, and drug target discovery.